Danshensu alleviates cardiac ischaemia/reperfusion injury by inhibiting autophagy and apoptosis via activation of mTOR signalling

Journal of Cellular and Molecular Medicine

Volumn 20, Issue 10, 2016, Pages 1908-1919

  Fan, Guanwei ^a   Yu, Jiahui ^a   Asare, Patrick Fordjour ^a   Wang, Lingyan ^a   Zhang, Han ^a   Zhang, Boli ^a   Zhu, Yan ^a   Gao, Xiumei ^a  

^a TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

apoptosis; autophagy; Danshensu; I R injury; mTOR

Indexed keywords

3 (3,4 DIHYDROXYPHENYL)LACTIC ACID; BECLIN 1; CASPASE 3; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PROTEIN BAX; PROTEIN P62; 3,4-DIHYDROXYPHENYLLACTIC ACID; BIOLOGICAL MARKER; CARDIOTONIC AGENT; CREATINE KINASE; LACTATE DEHYDROGENASE; LACTIC ACID DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; HEART MUSCLE ISCHEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; CARDIAC MUSCLE CELL; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; HEART FUNCTION TEST; METABOLISM; MYOCARDIAL REPERFUSION INJURY; NEWBORN; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; AUTOPHAGY; BIOMARKERS; CARDIOTONIC AGENTS; CELL SURVIVAL; CREATINE KINASE; GENE EXPRESSION REGULATION; HEART FUNCTION TESTS; L-LACTATE DEHYDROGENASE; LACTATES; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84978187221     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12883     Document Type: Article

References (42)

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007; 357: 1121–35.
2. Magro M, Garg S, Serruys PW. Revascularization treatment of stable coronary artery disease. Expert Opin Pharmacother. 2011; 12: 195–212.
3. Minamino T. Cardioprotection from ischemia/reperfusion injury: basic and translational research. Circ J. 2012; 76: 1074–82.
4. Nishida K, Kyoi S, Yamaguchi O, et al. The role of autophagy in the heart. Cell Death Differ. 2009; 16: 31–8.
5. Takemura G, Miyata S, Kawase Y, et al. Autophagic degeneration and death of cardiomyocytes in heart failure. Autophagy. 2006; 2: 212–4.
6. Hein S, Arnon E, Kostin S, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation. 2003; 107: 984–91.
7. Yan L, Vatner DE, Kim SJ, et al. Autophagy in chronically ischemic myocardium. Proc Natl Acad Sci USA. 2005; 102: 13807–12.
8. Luo Y, Lu S, Zhou P, et al. Autophagy: an exposing therapeutic target in atherosclerosis. J Cardiovasc Pharmacol. 2016; 67: 266–74.
9. Zhu H, Tannous P, Johnstone JL, et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest. 2007; 117: 1782–93.
10. Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol. 2008; 9: 1004–10.
11. Yan L, Sadoshima J, Vatner DE, et al. Autophagy in ischemic preconditioning and hibernating myocardium. Autophagy. 2009; 5: 709–12.
12. Sadoshima J. The role of autophagy during ischemia/reperfusion. Autophagy. 2008; 4: 402–3.
13. Movassagh M, Foo RS. Simplified apoptotic cascades. Heart Fail Rev. 2008; 13: 111–9.
14. Anversa P, Cheng W, Liu Y, et al. Apoptosis and myocardial infarction. Basic Res Cardiol. 1998; 93 (Suppl. 3): 8–12.
15. Buja LM, Entman ML. Modes of myocardial cell injury and cell death in ischemic heart disease. Circulation. 1998; 98: 1355–7.
16. Imahashi K, Schneider MD, Steenbergen C, et al. Transgenic expression of Bcl-2 modulates energy metabolism, prevents cytosolic acidification during ischemia, and reduces ischemia/reperfusion injury. Circ Res. 2004; 95: 734–41.
17. Hochhauser E, Kivity S, Offen D, et al. Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice. Am J Physiol Heart Circ Physiol. 2003; 284: H2351–9.
18. Gustafsson AB, Tsai JG, Logue SE, et al. Apoptosis repressor with caspase recruitment domain protects against cell death by interfering with Bax activation. J Biol Chem. 2004; 279: 21233–8.
19. Ma X, Liu H, Foyil SR, et al. Impaired autophagosome clearance contributes to cardiomyocyte death in ischemia/reperfusion injury. Circulation. 2012; 125: 3170–81.
20. Hariharan N, Zhai P, Sadoshima J. Oxidative stress stimulates autophagic flux during ischemia/reperfusion. Antioxid Redox Signal. 2011; 14: 2179–90.
21. Maiuri MC, Zalckvar E, Kimchi A, et al. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol. 2007; 8: 741–52.
22. Pattingre S, Tassa A, Qu X, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005; 122: 927–39.
23. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006; 124: 471–84.
24. Aoyagi T, Kusakari Y, Xiao CY, et al. Cardiac mTOR protects the heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2012; 303: H75–85.
25. Zhou X, Chan SW, Tseng HL, et al. Danshensu is the major marker for the antioxidant and vasorelaxation effects of Danshen (Salvia miltiorrhiza) water-extracts produced by different heat water-extractions. Phytomedicine. 2012; 19: 1263–9.
26. Zhao BL, Jiang W, Zhao Y, et al. Scavenging effects of Salvia miltiorrhiza on free radicals and its protection for myocardial mitochondrial membranes from ischemia-reperfusion injury. Biochem Mol Biol Int. 1996; 38: 1171–82.
27. Yin Y, Guan Y, Duan J, et al. Cardioprotective effect of Danshensu against myocardial ischemia/reperfusion injury and inhibits apoptosis of H9c2 cardiomyocytes via Akt and ERK1/2 phosphorylation. Eur J Pharmacol. 2013; 699: 219–26.
28. 2-induced injury by inhibiting mitochondrial permeability transition pore opening. J Ethnopharmacol. 2015; 175: 617–25.
29. Shahzad T, Kasseckert SA, Iraqi W, et al. Mechanisms involved in postconditioning protection of cardiomyocytes against acute reperfusion injury. J Mol Cell Cardiol. 2013; 58: 209–16.
30. Li YH, Yu B, Duan ZZ, et al. The coronary dilation effect of shen fu injection was mediated through NO. PLoS ONE. 2014; 9: e92415.
31. Ferrera R, Bopassa JC, Angoulvant D, et al. Post-conditioning protects from cardioplegia and cold ischemia via inhibition of mitochondrial permeability transition pore. J Heart Lung Transplant. 2007; 26: 604–9.
32. Yu J, Wang L, Akinyi M, et al. Danshensu protects isolated heart against ischemia reperfusion injury through activation of Akt/ERK1/2/Nrf2 signaling. Int J Clin Exp Med. 2015; 8: 14793–804.
33. Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy. 2007; 3: 452–60.
34. Yuan K, Huang C, Fox J, et al. Autophagy plays an essential role in the clearance of Pseudomonas aeruginosa by alveolar macrophages. J Cell Sci. 2012; 125: 507–15.
35. Ma X, Godar RJ, Liu H, et al. Enhancing lysosome biogenesis attenuates BNIP3-induced cardiomyocyte death. Autophagy. 2012; 8: 297–309.
36. Jung CH, Ro SH, Cao J, et al. mTOR regulation of autophagy. FEBS Lett. 2010; 584: 1287–95.
37. Huang S, Shu L, Easton J, et al. Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J Biol Chem. 2004; 279: 36490–6.
38. Sciarretta S, Volpe M, Sadoshima J. Mammalian target of rapamycin signaling in cardiac physiology and disease. Circ Res. 2014; 114: 549–64.
39. Wong M. Mammalian target of rapamycin (mTOR) pathways in neurological diseases. Biomedical journal. 2013; 36: doi:10.4103/2319-4170.110365.
40. Wang F, Ye P. Improving heart function by modulating myocardiocyte autophagy: a possible novel mechanism for cardiovascular protection of high-density lipoprotein. Lipids Health Dis. 2014; 13: 163.
41. Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ. 2002; 9: 99–100.
42. Cheng TO. Cardiovascular effects of Danshen. Int J Cardiol. 2007; 121: 9–22.